Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report - Takeaways - MDSpire

Depigmentation resembling vitiligo after neoadjuvant chemotherapy and pembrolizumab in early-stage triple-negative breast cancer: a case study

  • By

  • Yinglei Deng

  • Dahua Mao

  • Shaogang Zhang

  • Jing Wang

  • July 20, 2026

Share

  • 1

    Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis.

  • 2

    The combination of neoadjuvant chemotherapy and pembrolizumab has improved outcomes in early-stage TNBC.

  • 3

    A patient developed vitiligo-like depigmentation during pembrolizumab maintenance therapy after achieving a pathological complete response.

  • 4

    The depigmentation was asymptomatic and did not disrupt the planned immunotherapy course.

  • 5

    Further research is needed to understand the incidence and significance of immune-related depigmentation in breast cancer.

Original Source(s)

Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report

  • by Yinglei Deng, Dahua Mao, Shaogang Zhang, Jing Wang

  • July 20, 2026

Related Content

An FDG-first functional imaging approach in phaeochromocytoma and paraganglioma

Predicting cancer treatment outcomes using machine learning enabled clinical decision support systems

Lipid metabolic plasticity in glioblastoma: mechanisms, tumor microenvironment remodeling, and therapeutic opportunities